Sangamo Therapeutics (NASDAQ:SGMO) has been given a $25.00 price target by equities researchers at Piper Jaffray Companies in a research report issued to clients and investors on Wednesday, January 3rd. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 17.37% from the company’s current price.

Other analysts have also issued reports about the company. Wells Fargo & Co reissued an “outperform” rating and issued a $30.00 price target (up from $20.00) on shares of Sangamo Therapeutics in a research note on Tuesday, September 5th. Jefferies Group reissued a “buy” rating and issued a $18.00 price target on shares of Sangamo Therapeutics in a research note on Friday, October 13th. Zacks Investment Research raised Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Wednesday, November 15th. Wedbush reaffirmed a “hold” rating and issued a $6.00 price objective on shares of Sangamo Therapeutics in a research note on Wednesday, November 15th. Finally, BidaskClub raised Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Friday, December 29th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Sangamo Therapeutics currently has an average rating of “Buy” and an average price target of $18.83.

How to Become a New Pot Stock Millionaire

Shares of Sangamo Therapeutics (NASDAQ SGMO) traded up $0.40 during mid-day trading on Wednesday, hitting $21.30. The stock had a trading volume of 1,304,251 shares, compared to its average volume of 1,310,000. Sangamo Therapeutics has a twelve month low of $3.35 and a twelve month high of $21.90. The stock has a market capitalization of $1,800.00, a PE ratio of -30.87 and a beta of 3.15. The company has a current ratio of 5.64, a quick ratio of 5.64 and a debt-to-equity ratio of 0.02.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.04. The firm had revenue of $11.81 million during the quarter, compared to analysts’ expectations of $10.37 million. Sangamo Therapeutics had a negative return on equity of 31.81% and a negative net margin of 157.66%. The firm’s quarterly revenue was up 333.0% compared to the same quarter last year. During the same quarter last year, the business posted ($0.27) EPS. analysts forecast that Sangamo Therapeutics will post -0.73 EPS for the current year.

In other Sangamo Therapeutics news, VP Curt A. Herberts III sold 16,630 shares of Sangamo Therapeutics stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $16.13, for a total transaction of $268,241.90. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, VP Edward R. Conner sold 5,000 shares of Sangamo Therapeutics stock in a transaction that occurred on Monday, January 8th. The stock was sold at an average price of $17.11, for a total value of $85,550.00. The disclosure for this sale can be found here. Insiders have sold a total of 58,433 shares of company stock worth $979,696 over the last three months. 5.50% of the stock is currently owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Blair William & Co. IL increased its holdings in shares of Sangamo Therapeutics by 4.3% in the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after acquiring an additional 500 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Sangamo Therapeutics by 0.4% in the 1st quarter. Dimensional Fund Advisors LP now owns 128,764 shares of the biopharmaceutical company’s stock valued at $670,000 after acquiring an additional 513 shares during the last quarter. Principal Financial Group Inc. boosted its position in Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 832 shares during the period. Schwab Charles Investment Management Inc. boosted its position in Sangamo Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 267,293 shares of the biopharmaceutical company’s stock valued at $2,353,000 after purchasing an additional 1,558 shares during the period. Finally, Voya Investment Management LLC boosted its position in Sangamo Therapeutics by 10.7% during the 2nd quarter. Voya Investment Management LLC now owns 33,809 shares of the biopharmaceutical company’s stock valued at $298,000 after purchasing an additional 3,270 shares during the period. Institutional investors and hedge funds own 64.09% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Sangamo Therapeutics (SGMO) Given a $25.00 Price Target by Piper Jaffray Companies Analysts” was first published by Marea Informative and is owned by of Marea Informative. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.mareainformativa.com/2018/01/29/sangamo-therapeutics-sgmo-given-a-25-00-price-target-at-piper-jaffray-companies-updated-updated-updated.html.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Analyst Recommendations for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.